Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110471088> ?p ?o ?g. }
- W2110471088 endingPage "1648" @default.
- W2110471088 startingPage "1638" @default.
- W2110471088 abstract "K-ras mutations promote angiogenesis in lung cancer and contribute to the drug resistance of cancer cells. It is not clear whether K-ras mutated adenocarcinomas are sensitive to anti-angiogenic therapy with monoclonal antibodies (mAbs) that target vascular endothelial growth factor (VEGF). Anti-angiogenic mAbs are usually delivered systemically, but only a small proportion reaches the lung after intravenous injection. We investigated the relevance of a non-invasive pulmonary route for the delivery of anti-VEGF mAbs in the mouse K-rasLA1 model. We found that pulmonary delivery of these mAbs significantly reduced the number of tumor lesions and inhibited malignant progression. The antitumor effect involves the VEGFR2-dependent inhibition of blood vessel growth, which impairs tumor proliferation. Pharmacokinetic analysis of aerosolized anti-VEGF showed its low rate of passage into the bloodstream, suggesting that this delivery route is associated with reduced systemic side effects. Our findings highlight the value of the aerosol route for administration of anti-angiogenic mAbs in pulmonary adenocarcinoma with K-ras activating-mutations." @default.
- W2110471088 created "2016-06-24" @default.
- W2110471088 creator A5016372587 @default.
- W2110471088 creator A5027068255 @default.
- W2110471088 creator A5027099014 @default.
- W2110471088 creator A5039278929 @default.
- W2110471088 creator A5041769783 @default.
- W2110471088 creator A5043422740 @default.
- W2110471088 creator A5043441875 @default.
- W2110471088 creator A5049291969 @default.
- W2110471088 creator A5049677090 @default.
- W2110471088 creator A5053712155 @default.
- W2110471088 creator A5056268347 @default.
- W2110471088 creator A5070999281 @default.
- W2110471088 creator A5074410916 @default.
- W2110471088 creator A5077270282 @default.
- W2110471088 creator A5078872119 @default.
- W2110471088 date "2014-11-01" @default.
- W2110471088 modified "2023-10-12" @default.
- W2110471088 title "VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations" @default.
- W2110471088 cites W1492974076 @default.
- W2110471088 cites W1593728653 @default.
- W2110471088 cites W1611210979 @default.
- W2110471088 cites W1833302978 @default.
- W2110471088 cites W1969371715 @default.
- W2110471088 cites W1979242769 @default.
- W2110471088 cites W1989402742 @default.
- W2110471088 cites W1996045402 @default.
- W2110471088 cites W1996970629 @default.
- W2110471088 cites W2000292756 @default.
- W2110471088 cites W2001343980 @default.
- W2110471088 cites W2011984832 @default.
- W2110471088 cites W2017322644 @default.
- W2110471088 cites W2019188597 @default.
- W2110471088 cites W2031486360 @default.
- W2110471088 cites W2039588686 @default.
- W2110471088 cites W2043768346 @default.
- W2110471088 cites W2049714385 @default.
- W2110471088 cites W2050249255 @default.
- W2110471088 cites W2050676588 @default.
- W2110471088 cites W2055854781 @default.
- W2110471088 cites W2057006907 @default.
- W2110471088 cites W2058213101 @default.
- W2110471088 cites W2062995866 @default.
- W2110471088 cites W2068562114 @default.
- W2110471088 cites W2109334930 @default.
- W2110471088 cites W2114331080 @default.
- W2110471088 cites W2114937594 @default.
- W2110471088 cites W2118185746 @default.
- W2110471088 cites W2119490571 @default.
- W2110471088 cites W2134400475 @default.
- W2110471088 cites W2138377963 @default.
- W2110471088 cites W2144215173 @default.
- W2110471088 cites W2144718958 @default.
- W2110471088 cites W2145835533 @default.
- W2110471088 cites W2151178480 @default.
- W2110471088 cites W2154200023 @default.
- W2110471088 cites W2156483316 @default.
- W2110471088 cites W2166084034 @default.
- W2110471088 cites W2166923287 @default.
- W2110471088 cites W2166955831 @default.
- W2110471088 cites W2324967303 @default.
- W2110471088 cites W2405042525 @default.
- W2110471088 cites W4252851641 @default.
- W2110471088 cites W59174886 @default.
- W2110471088 doi "https://doi.org/10.4161/mabs.34454" @default.
- W2110471088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4623465" @default.
- W2110471088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25484066" @default.
- W2110471088 hasPublicationYear "2014" @default.
- W2110471088 type Work @default.
- W2110471088 sameAs 2110471088 @default.
- W2110471088 citedByCount "26" @default.
- W2110471088 countsByYear W21104710882015 @default.
- W2110471088 countsByYear W21104710882016 @default.
- W2110471088 countsByYear W21104710882017 @default.
- W2110471088 countsByYear W21104710882018 @default.
- W2110471088 countsByYear W21104710882019 @default.
- W2110471088 countsByYear W21104710882020 @default.
- W2110471088 countsByYear W21104710882021 @default.
- W2110471088 countsByYear W21104710882023 @default.
- W2110471088 crossrefType "journal-article" @default.
- W2110471088 hasAuthorship W2110471088A5016372587 @default.
- W2110471088 hasAuthorship W2110471088A5027068255 @default.
- W2110471088 hasAuthorship W2110471088A5027099014 @default.
- W2110471088 hasAuthorship W2110471088A5039278929 @default.
- W2110471088 hasAuthorship W2110471088A5041769783 @default.
- W2110471088 hasAuthorship W2110471088A5043422740 @default.
- W2110471088 hasAuthorship W2110471088A5043441875 @default.
- W2110471088 hasAuthorship W2110471088A5049291969 @default.
- W2110471088 hasAuthorship W2110471088A5049677090 @default.
- W2110471088 hasAuthorship W2110471088A5053712155 @default.
- W2110471088 hasAuthorship W2110471088A5056268347 @default.
- W2110471088 hasAuthorship W2110471088A5070999281 @default.
- W2110471088 hasAuthorship W2110471088A5074410916 @default.
- W2110471088 hasAuthorship W2110471088A5077270282 @default.
- W2110471088 hasAuthorship W2110471088A5078872119 @default.
- W2110471088 hasBestOaLocation W21104710881 @default.
- W2110471088 hasConcept C105702510 @default.